Cerebral Therapeutics™ Raises Series A Extension Financing to Advance Clinical-Stage Drug Device Combination Therapy to Phase 3 Readiness for Adult Refractory Epilepsy

Written By Distill

Financing Led by Granite Point Capital and Vivo Capital
Cerebral Therapeutics™ Prepares IND and Clinical Development Program in the U.S.

Aurora, CO., March 8, 2019

Read Full Article

Distill https://www.distillagency.com
Previous

First clinical trial of reformulated epileptic drug to treat medically refractory epilepsy
Next

Cerebral Therapeutics™ Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy